IP Library Granted Patent US 7,118,763
Granted Patent B2
US 7,118,763 · App. 10/920,422 · Granted Oct 10, 2006

Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,118,763
App. No.
10/920,422
Granted
Oct 10, 2006
Kind
B2
Abstract

Sustained-release microparticle composition. The microparticle composition can be formulated to provide multi-phasic release. In one aspect, the composition includes microparticles having more than one rate of release. In another aspect, the composition includes microparticles that exhibit diffusional release and microparticles that exhibit biodegradation release.

Claims (8)

1. A method of making a multi-phasic sustained-release microparticle composition, comprising:

dissolving in a solvent an active agent and a biodegradable and biocompatible polymer to form an organic phase, wherein the active agent is selected from the group consisting of risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing;

extracting the solvent to form microparticles; and

combining microparticles having a plurality of sizes to thereby form a composition that delivers the active agent in a multi-phasic manner.

2. A method of making a multi-phasic sustained-release microparticle composition, comprising:

dissolving in a solvent an active agent and a biodegradable and biocompatible polymer to form an organic phase, wherein the active agent is selected from the group consisting of risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing;

extracting the solvent to form microparticles; and

combining microparticles exhibiting diffusional release and microparticles exhibiting biodegradation release to thereby form a composition that delivers the active agent in a multi-phasic manner.

Assignments (8)
RELEASE OF PATENT SECURITY AGREEMENT (FIRST LIEN) Recorded Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0548 →
RELEASE BY SECURED PARTY (SECOND LIEN) Recorded Oct 12, 2012
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
Reel/Frame 029116/0379 →
PATENT SECURITY AGREEMENT (FIRST LIEN) Recorded Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0186 →
PATENT SECURITY AGREEMENT (SECOND LIEN) Recorded Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0245 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2009
From: MEDISORB TECHNOLOGIES INTERNATIONAL, L.P.
To: ALKERMES CONTROLLED THERAPEUTICS, INC. II
Reel/Frame 022214/0615 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2009
From: MESENS, JEAN
To: JANSSEN PHARMACEUTICA
Reel/Frame 022203/0575 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2009
From: RICKEY, MICHAEL E.; ATKINS, THOMAS J.
To: MEDISORB TECHNOLOGIES INTERNATIONAL, L.P.
Reel/Frame 022151/0421 →
MERGER Recorded Sep 6, 2006
From: ALKERMES CONTROLLED THERAPEUTICS INC. II
To: ALKERMES, INC.
Reel/Frame 018207/0226 →